Ocean Biomedical, Inc. (OCEA) intrinsic value & 10-year financials
Ocean Biomedical, Inc. (OCEA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $5.5K
- Revenue (FY2024)
- —
- ROIC (10-yr avg)
- 55.2%
- Free cash flow (FY2024)
- —
OCEA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$9.5M | -$0.34 | — | — | 10.8% |
| FY2023 | — | -$114.5M | -$4.35 | — | — | 130.7% |
| FY2022 | — | -$958.4K | -$0.74 | — | — | 24.0% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ocean Biomedical, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Ocean Biomedical, Inc. has earned high returns on invested capital, averaging 55.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Ocean Biomedical, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Ocean Biomedical, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.